Europe
Pharming Group N.V. announced it has received European Medicines Agency approval of a Type II Variation for a new production facility for the Company’s lead product, RUCONEST®.
Evotec SE announced an increase in its profitability guidance for the financial year 2019 after the preliminary completion of the latest evaluation of the Company’s financial performance.
Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimer’s market, which isn’t as unusual or unexpected as it initially sounds.
A U.K. study confirmed that the use of blood-thinning medications benefits all heart failure patients, regardless of whether or not those patients have been diagnosed with atrial fibrillation.
Albert Baehny, chairman of the board of directors, said the company looks forward to the coming challenges of 2020, including the naming of a new CEO.
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.
The researchers essentially identified a new T-cell and its receptor that appears able to search out and kill a broad range of cancer cells, including lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells.
Watson-Marlow Fluid Technology Group has launched BioPure silicone transfer tubing to provide a safe, reliable and value-based solution for a wide range of bioprocess fluid transfer applications.
The funds will allow the company to accelerate the development of its chemotherapy drug candidate targeting solid tumors
AstraZeneca’s Imfinzi (durvalumab) and tremelimumab were granted Orphan Drug designation by the U.S. Food and Drug Administration as a possible treatment for hepatocellular carcinoma.
PRESS RELEASES